drug

Semaglutide

semaglutide

MeSH C000591245

as of 2026-07-01

Add to landscape Monitor this Compare this Ask about this

at a glance

small molecule

Pre-approval / investigational in the US

Developed by Centre for Addiction and Mental Health

2 trials in the graph

Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality

small molecule

Indications

Investigational (via trials)

Schizo Affective Disorder Weight Loss Bipolar Disorder Body Weight Obesity Schizophrenia Spectrum Disorders Bipolar II Disorder Obesity Psychotic Disorders Weight Loss GLP - 1 Bipolar I Disorder

Trials

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

NCT07213466Phase 4Recruiting

Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity

NCT05333003—Active Not Recruiting

KOLs & investigators

Margaret K Hahn, PhD, MDKOL score 10

Mark A Frye, M.D.KOL score 5

Facts & assertions

0 sourced

No assertions recorded for this entity.

relationships

The graph out of here

developer

Centre for Addiction and Mental Health

company

trial

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

PHASE4

trial

Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity

trial

indication

Schizo Affective Disorder

indication

Weight Loss

indication

Bipolar Disorder

indication

Body Weight

indication

KOL

Margaret K Hahn, PhD, MD

KOL score 10

person

Mark A Frye, M.D.

KOL score 5

person